Ikarian Capital »

Edgewise Therapeutics shares owned by Ikarian Capital

Quarter-by-quarter ownership of Edgewise Therapeutics (EWTX) shares owned by Ikarian Capital from 13F filings

Historical chart of Ikarian Capital investment in Edgewise Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Edgewise Therapeutics held by Ikarian Capital consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Edgewise Therapeutics by Ikarian Capital

Quarter filed Position value Share count Share price at filing
2023-12-31 $3.0M 270k 10.94

More positions owned by Ikarian Capital

Argenx Se Sponsored Adr (ARGX)
Krystal Biotech Call Option (KRYS)
Cytokinetics Com New (CYTK)
Alnylam Pharmaceuticals Call Option (ALNY)
Spdr Ser Tr S&p Biotech Put Option (XBI)
Crispr Therapeutics Namen Akt (CRSP)
Eli Lilly & Co. Put Option (LLY)
Sarepta Therapeutics (SRPT)
Prothena Corp SHS Call Option (PRTA)
Amylyx Pharmaceuticals (AMLX)
Nuvalent Inc-a (NUVL)
Immunovant (IMVT)
Crinetics Pharmaceuticals In (CRNX)
Soleno Therapeutics (SLNO)
Eyepoint Pharmaceuticals Com New (EYPT)

View all positions for Ikarian Capital

Top funds holding Edgewise Therapeutics

OrbiMed Advisors
Viking Global Investors
Deerfield Management Company
EcoR1 Capital
Baker Bros. Advisors
Frazier Life Sciences Management
Citadel Advisors
Cormorant Asset Management
Vanguard Group
Henderson Group
Hudson Bay Capital Management
Logos Global Management
Goldman Sachs Group
Barclays
Opaleye Management

View all funds holding Edgewise Therapeutics